A detailed history of Quest Partners LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 29,833 shares of EXEL stock, worth $1.01 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
29,833
Previous 41,316 27.79%
Holding current value
$1.01 Million
Previous $928 Million 16.61%
% of portfolio
0.07%
Previous 0.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$21.96 - $27.6 $252,166 - $316,930
-11,483 Reduced 27.79%
29,833 $774 Million
Q2 2024

Aug 06, 2024

BUY
$20.34 - $23.73 $839,431 - $979,337
41,270 Added 89717.39%
41,316 $928 Million
Q1 2024

May 09, 2024

SELL
$20.17 - $23.93 $295,006 - $350,000
-14,626 Reduced 99.69%
46 $1.09 Million
Q4 2023

Feb 09, 2024

BUY
$19.25 - $24.13 $282,436 - $354,035
14,672 New
14,672 $352 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.